RNA Replication For Biginners in Molecular Medicine By Ngenja Bidii – Video


RNA Replication For Biginners in Molecular Medicine By Ngenja Bidii
RNA synthesis in Eukaryote s involve 3 stages which include; intiation,elongation and termination.During Intiation of transcription,RNA-polymerase iii with the three sub-unit known as holo-enzyme binds to the promoter site which is mostly the TATA box.Successfully binding is followed by elongation process which involve addition of dNTPs as catalysed by core-enzyme.A core -enzyme is just a holo-enzyme lacking the sigma sub-unit. Upon reach of termination signal the synthesis is terminated.The termination signal is usually palindromic in sequencei.e can be read same from both directons.That how the synthesis occurs in brief.Am preparing for much details in my next video.Keep checking f0r updates.From:NgejaBidiiViews:1 0ratingsTime:04:41More inEducation

Continue reading here:

RNA Replication For Biginners in Molecular Medicine By Ngenja Bidii - Video

Coast to Coast AM – Oct 02 2012 – Space Travel


Coast to Coast AM - Oct 02 2012 - Space Travel Creature Forensics C2CAM
Date: 10-02-12 Host: George Noory Guests: William Louis McDonald , LA Marzulli Appearing during the middle two hours, forensic artist and alternative investigator, Bill McDonald, shared updates on several of his projects including the biology of the Loch Ness monster, as well as how advances in molecular medicine and nanotechnology will facilitate future long distance space travel beyond the orbit of Mars. Biological beings cannot survive deep space travels or warp drive, as they will acquire brittle bone disease and irreversible tissue damage, he said. So, one solution, he detailed, is using applied nanotechnology, which is to say loading millions of microscopic nano-assemblers, microsurgical bots and nanites with default medical support programming into each individual space traveler. Such technology would in effect turn the astronauts into cybernetic organisms or cyborgs, he noted. This correlates with reports of certain #39;Grey #39; ETs who #39;ve been described as being partly robotic, as well descriptions of the Roswell craft and aliens, in which the vehicle and flight crew were said to be merged into a "combined being," McDonald cited. Regarding his research into Nessie and sea monsters, he posited that certain types of eels could occasionally produce a single rare individual that is truly a giant aquatic monster, feeding both in the water and crawling around on land (see related illustration below). He correlated his theory to the work of Jeremy Wade of the River Monsters ...From:C2CPlanetViews:101 2ratingsTime:02:30:01More inEducation

More here:

Coast to Coast AM - Oct 02 2012 - Space Travel

Coast To Coast AM Space Travel


Coast To Coast AM Space Travel Creature Forensics October 02 2012
WATCH THE LATEST VIDEO THAT CAME OUT TODAY HERE http://www.youtube.com http://www.jetstreamnews.com If You Use Twitter heres the Twitter address or just click the twitter link on the right of the channel page twitter.com Date: 10-02-12 Host: George Noory Guests: William Louis McDonald , LA Marzulli Appearing during the middle two hours, forensic artist and alternative investigator, Bill McDonald, shared updates on several of his projects including the biology of the Loch Ness monster, as well as how advances in molecular medicine and nanotechnology will facilitate future long distance space travel beyond the orbit of Mars. Biological beings cannot survive deep space travels or warp drive, as they will acquire brittle bone disease and irreversible tissue damage, he said. So, one solution, he detailed, is using applied nanotechnology, which is to say loading millions of microscopic nano-assemblers, microsurgical bots and nanites with default medical support programming into each individual space traveler. Such technology would in effect turn the astronauts into cybernetic organisms or cyborgs, he noted. This correlates with reports of certain #39;Grey #39; ETs who #39;ve been described as being partly robotic, as well descriptions of the Roswell craft and aliens, in which the vehicle and flight crew were said to be merged into a "combined being," McDonald cited. Regarding his research into Nessie and sea monsters, he posited that certain types of eels could occasionally produce a single rare ...From:USAMOONBASEViews:48 0ratingsTime:02:30:30More inEducation

Read the original here:

Coast To Coast AM Space Travel

Nitric Oxide is The Most Important Molecule – Video


Nitric Oxide is The Most Important Molecule
Dr Nathan Bryan, Professor of Molecular Medicine explains how Nitric Oxide is the most important molecule produced by your blood vessels. As we age our body loses its ability to make Nitric Oxide. Research has shown that its that event that early event the inability to make Nitric Oxide that puts our body at risk to developing cardiovascular disease.From:John ThompsonViews:2 0ratingsTime:00:32More inEducation

Go here to read the rest:

Nitric Oxide is The Most Important Molecule - Video

BUSINESS WIRE: The 2nd meeting of the series Days of Molecular Medicine

BUSINESS WIRE: The 2nd meeting of the series Days of Molecular Medicine

25.10.2012, 10:00:06

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

The Translational Science of Rare Diseases : From Rare to Care

PARIS --(BUSINESS WIRE)-- 25.10.2012 --

Each year the American Association for the Advancement of Science, which publishes the prestigious journals Science and Science Translational Medicine, the Karolinska institute in Stockholm, the DMMGF foundation and the Fondation Ipsen organise a series of meetings entitled Days of Molecular Medicine. This year the Institute for Molecular Biotechnology (Vienna) was also involved in the partnership. The meetings are highly regarded in the field of translational medicine, which bridges the gap between fundamental research and medical application. The latest event took place from 8-10 October in Vienna, Austria. Several well known scientists, including the Nobel Prize Eric Kandel attended the meeting.

Entitled "The translational science of rare diseases: Rare for Care", the meeting focused on an original topic with far-reaching consequences: research into rare illnesses and how it can lead to discovering therapies, including for common illnesses. Rare illnesses are also known as orphan diseases because they affect few patients and can therefore be neglected. Yet, although each rare illness only affects a few patients, together, they affect a lot of people. Their treatment also plays an essential role in adapting our approach to human physiology and pathology. Many rare illnesses have genetic origins that can be elucidated. Pinpointing the gene or genes involved enables a protein or a biochemical path to be targeted and acted on, using gene therapy or drugs. Cystic fibrosis is a remarkable example of this. Many pathogenic mutations have been identified and their mechanism brought to light through research into the disease. As Peter Mueller (Cambridge, USA) demonstrated in Vienna, this resulted in a drug formulation that can increase a patient's life expectancy by twenty years!

Concerning gene therapy, Alain Fischer (Hpital Necker, Paris, France) presented his pioneering work, while several others presented on-going trials to treat Canavan disease or blindness. Many extremely rare and newly identified illnesses were also presented, among them those discovered through a special programme instigated by the American National Institute of Health.

About the Fondation Ipsen

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialisation of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Mdecine et Recherche, dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation Ipsen has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature, Cell and Science. The Fondation Ipsen produced several hundreds publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.

Read more here:

BUSINESS WIRE: The 2nd meeting of the series Days of Molecular Medicine

The 2nd meeting of the series Days of Molecular Medicine

PARIS--(BUSINESS WIRE)--

Each year the American Association for the Advancement of Science, which publishes the prestigious journals Science and Science Translational Medicine, the Karolinska institute in Stockholm, the DMMGF foundation and the Fondation Ipsen organise a series of meetings entitled Days of Molecular Medicine. This year the Institute for Molecular Biotechnology (Vienna) was also involved in the partnership. The meetings are highly regarded in the field of translational medicine, which bridges the gap between fundamental research and medical application. The latest event took place from 8-10 October in Vienna, Austria. Several well known scientists, including the Nobel Prize Eric Kandel attended the meeting.

Entitled The translational science of rare diseases: Rare for Care, the meeting focused on an original topic with far-reaching consequences: research into rare illnesses and how it can lead to discovering therapies, including for common illnesses. Rare illnesses are also known as orphan diseases because they affect few patients and can therefore be neglected. Yet, although each rare illness only affects a few patients, together, they affect a lot of people. Their treatment also plays an essential role in adapting our approach to human physiology and pathology. Many rare illnesses have genetic origins that can be elucidated. Pinpointing the gene or genes involved enables a protein or a biochemical path to be targeted and acted on, using gene therapy or drugs. Cystic fibrosis is a remarkable example of this. Many pathogenic mutations have been identified and their mechanism brought to light through research into the disease. As Peter Mueller (Cambridge, USA) demonstrated in Vienna, this resulted in a drug formulation that can increase a patients life expectancy by twenty years!

Concerning gene therapy, Alain Fischer (Hpital Necker, Paris, France) presented his pioneering work, while several others presented on-going trials to treat Canavan disease or blindness. Many extremely rare and newly identified illnesses were also presented, among them those discovered through a special programme instigated by the American National Institute of Health.

About the Fondation Ipsen

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialisation of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Mdecine et Recherche, dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation Ipsen has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature, Cell and Science. The Fondation Ipsen produced several hundreds publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.

Go here to see the original:

The 2nd meeting of the series Days of Molecular Medicine

Dan R. Littman, MD, PhD, Elected Member of Prestigious Institute of Medicine

Newswise NYU Langone Medical Center announced today that Dan R. Littman, MD, PhD, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology, a professor of pathology and microbiology, and a faculty member in the Molecular Pathogenesis program in the Skirball Institute of Biomolecular Medicine, has been elected a member of the Institute of Medicine (IOM). Seventy new members and ten foreign associates were named during the IOMs 42nd annual meeting on October 15. Dr. Littman is NYU School of Medicines ninth faculty member to be elected into the IOM.

Being elected into the IOM is an extraordinary honor and is evidence of the remarkable and important contributions Dr. Littman has made to science and medicine, said Robert I. Grossman, MD, dean & CEO at NYU Langone Medical Center. We congratulate Dr. Littman on receiving this significant distinction.

A renowned immunologist and molecular biologist, Dr. Littman has made seminal contributions to numerous fields including understanding the molecular basis of immune recognition, HIV pathogenesis, T-cell differentiation and selection and most recently, the role of commensal bacteria in immune system development and regulation. Dr. Littman is a Howard Hughes Medical Institute Investigator, a member in the National Academy of the Sciences, and is a fellow in both the American Academy of Arts and Sciences and the American Academy of Microbiology.

Dr. Littman has been a leader in applying molecular biology and mouse genetics to study specification of T lymphocyte lineages and the differentiation of inflammatory T helper cells. Early in his career Dr. Littman isolated the genes for the CD4 and CD8 co-receptors and determined how their expression is regulated and their signaling influences selection of helper and cytotoxic cells. His group subsequently went on to demonstrate that CD4 and CCR5 collaborate as co-receptors for HIV, leading to therapeutic targeting of CCR5 in AIDS, and the demonstration that HIV evades host innate responses by failing to replicate in dendritic cells. In recent work, Dr. Littman discovered that the nuclear receptor ROR-gamma-t regulates differentiation of Th17 cells and lymphoid tissue inducer cells, and identified compounds that inhibit its activity and may be effective for autoimmune disease therapy. He identified a commensal gut bacterium that selectively induces Th17 cells and promotes autoimmunity in mice, which may be relevant for human diseases, like rheumatoid arthritis, thought to be influenced by imbalanced microbiota. His work has thus had major impact in both immunology and virology, and is being translated into therapies for multiple diseases.

Established in 1970 by the National Academy of Sciences, IOM is recognized as a national resource for independent, scientifically informed analysis and recommendations on health issues. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.

"The Institute of Medicine is greatly enriched by the addition of our newly elected colleagues, each of whom has significantly advanced health and medicine," said IOM President Harvey V. Fineberg. "Through their research, teaching, clinical work, and other contributions, these distinguished individuals have inspired and served as role models to others. We look forward to drawing on their knowledge and skills to improve health through the work of the IOM."

The newly elected members raise IOM's total active membership to 1,732 and the number of foreign associates to 112. With an additional 84 members holding emeritus status, IOM's total membership is 1,928. IOM's charter ensures diversity of talent among the Institute's membership by requiring at least one-quarter of the members to be selected from fields outside the health professions, such as engineering, social sciences, law, and the humanities.

About NYU Langone Medical Center NYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one of the nations premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals Tisch Hospital, its flagship acute care facility; the Rusk Institute of Rehabilitation Medicine, the worlds first university-affiliated facility devoted entirely to rehabilitation medicine; the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology; and Hassenfeld Pediatric Center, a comprehensive pediatric hospital supporting a full array of childrens health services across the Medical Center plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The medical centers tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research. For more information, go to http://www.NYULMC.org.

More here:

Dan R. Littman, MD, PhD, Elected Member of Prestigious Institute of Medicine

Dan R. Littman, M.D., Ph.D., elected member of prestigious Institute of Medicine

Public release date: 16-Oct-2012 [ | E-mail | Share ]

Contact: Deborah Sabalusky Deborah.Sabalusky@nyumc.org 212-404-3567 NYU Langone Medical Center / New York University School of Medicine

NYU Langone Medical Center announced today that Dan R. Littman, MD, PhD, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology, a professor in the departments of pathology and microbiology, and a faculty member in the Molecular Pathogenesis program in the Skirball Institute of Biomolecular Medicine, has been elected a member of the Institute of Medicine (IOM). Seventy new members and ten foreign associates were named during the IOM's 42nd annual meeting on October 15. Dr. Littman is NYU School of Medicine's ninth faculty member to be elected into the IOM.

"Being elected into the IOM is an extraordinary honor and is evidence of the remarkable and important contributions Dr. Littman has made to science and medicine," said Robert I. Grossman, MD, dean & CEO at NYU Langone Medical Center. "We congratulate Dr. Littman on receiving this significant distinction."

A renowned immunologist and molecular biologist, Dr. Littman has made seminal contributions to numerous fields including understanding the molecular basis of immune recognition, HIV pathogenesis, T-cell differentiation and selection and most recently, the role of commensal bacteria in immune system development and regulation. Dr. Littman is a Howard Hughes Medical Institute Investigator, a member in the National Academy of the Sciences, and is a fellow in both the American Academy of Arts and Sciences and the American Academy of Microbiology.

Dr. Littman has been a leader in applying molecular biology and mouse genetics to study specification of T lymphocyte lineages and the differentiation of inflammatory T helper cells. Early in his career Dr. Littman isolated the genes for the CD4 and CD8 co-receptors and determined how their expression is regulated and their signaling influences selection of helper and cytotoxic cells. His group subsequently went on to demonstrate that CD4 and CCR5 collaborate as co-receptors for HIV, leading to therapeutic targeting of CCR5 in AIDS, and the demonstration that HIV evades host innate responses by failing to replicate in dendritic cells. In recent work, Dr. Littman discovered that the nuclear receptor ROR-gamma-t regulates differentiation of Th17 cells and lymphoid tissue inducer cells, and identified compounds that inhibit its activity and may be effective for autoimmune disease therapy. He identified a commensal gut bacterium that selectively induces Th17 cells and promotes autoimmunity in mice, which may be relevant for human diseases, like rheumatoid arthritis, thought to be influenced by imbalanced microbiota. His work has thus had major impact in both immunology and virology, and is being translated into therapies for multiple diseases.

Established in 1970 by the National Academy of Sciences, IOM is recognized as a national resource for independent, scientifically informed analysis and recommendations on health issues. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.

"The Institute of Medicine is greatly enriched by the addition of our newly elected colleagues, each of whom has significantly advanced health and medicine," said IOM President Harvey V. Fineberg. "Through their research, teaching, clinical work, and other contributions, these distinguished individuals have inspired and served as role models to others. We look forward to drawing on their knowledge and skills to improve health through the work of the IOM."

The newly elected members raise IOM's total active membership to 1,732 and the number of foreign associates to 112. With an additional 84 members holding emeritus status, IOM's total membership is 1,928. IOM's charter ensures diversity of talent among the Institute's membership by requiring at least one-quarter of the members to be selected from fields outside the health professions, such as engineering, social sciences, law, and the humanities.

###

Go here to see the original:

Dan R. Littman, M.D., Ph.D., elected member of prestigious Institute of Medicine

New hope for leukemia patients

Kochi, Oct 15 (UNI)

Amrita Centre for Nanosciences and Molecular Medicine, part of the Amrita Institute of Medical Sciences and Research Centre has claimed to have discovered a potential cure for drug resistant leukemia.

Chronic Myeloid Leukemia (CML) responds well to a drug named 'Imatinib', however, when drug resistance sets in, which is in about 20-25 per cent of the cases, the patients has little chance of survival, a press release said here today.

Drug resistance was due to certain point mutations in the leukemia cells as a result of which the cells find an alternative pathway for survival, preventing the drug from killing the cancer cells, it said.

The Centre has developed a nanomedicine which had shown significant ability to kill the drug reststant cancer cells.

The nanomedicine was developed over the past three years and has shown success in in-vitro (or cell line based) studies, it added.

The Centre was now conducting animal trials or pre-clinical studies of the drug, it said, adding that it is expected that if pre-clinical trials are successful the new nano medicine can be submitted for clinical trial after approval from the government.

This was the first such discovery in the world of nanomedicine that effectively solves the problem of severe drug resistance in blood cancers.

The senior scientists involved in the research and development was Dr Manzoor Koyakutty, Professor and Dr Shantikumar Nair, Centre Director and Dean of Research.

Clinicians from the hospital who are involved in the research are Dr Pavithran, Dr Neeraj and Dr Prabhu. The PhD student who has worked on this as part of her PhD thesis is Archana Ratnakumari, it added.

Go here to read the rest:

New hope for leukemia patients

Dr. Don Cleveland of Ludwig Institute for Cancer Research elected to Institute of Medicine

Public release date: 15-Oct-2012 [ | E-mail | Share ]

Contact: Rachel Steinhardt rsteinhardt@licr.org 646-371-7394 Ludwig Institute for Cancer Research

New York, NY, October 15, 2012Don W. Cleveland, PhD, Member of the Ludwig Institute for Cancer Research and chair of the UC San Diego Department of Cellular and Molecular Medicine has been elected to the Institute of Medicine (IOM). Election to the IOM is one of the highest honors in the fields of health and medicine.

Established in 1970 by the National Academy of Sciences, the IOM serves as an advisory organization to Congress and policy makers on important health questions. During the past year projects included health IT and patient safety, treatment of post-traumatic stress disorder, nutrition rating systems and graphics on food packaging, and studies of environmental factors in breast cancer.

Cleveland's pioneering discoveries of the mechanisms of chromosome movement and cell-cycle control during normal cellular division, as well as of the principles of neuronal cell development and their relationship to the defects that contribute to inherited neurodegenerative disease, led to his being named to the American Academy of Arts & Sciences and the National Academy of Sciences in 2006.

Most recently, his research has achieved a significant breakthrough in treating Huntington's disease, an inherited and degenerative brain disorder for which there is no cure. A one-time injection of a new DNA-based drug treatment known as ASO (short for antisense oligonucleotide) blocked the activity of the gene whose mutation causes the disease. A single treatment silenced the mutated gene responsible for the disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.

Cleveland received his Ph.D. in biochemistry from Princeton University. Following his post-doctoral work at UC San Francisco, he was a professor at Johns Hopkins University School of Medicine until joining the Ludwig Institute for Cancer Research at UC San Diego in 1995.

###

About the Ludwig Institute for Cancer Research

The Ludwig Institute is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research. http://www.licr.org

See the rest here:

Dr. Don Cleveland of Ludwig Institute for Cancer Research elected to Institute of Medicine

US pair share chemistry Nobel for cell receptors

Robert Lefkowitz and Brian Kobilka of the United States won the Nobel Prize for Chemistry on Wednesday for identifying a class of cell receptor, yielding vital insights into how the body works at the molecular level.

The big beneficiary of this fundamental work is medicine, the Nobel committee declared.

The pair were honoured for discovering a key component of cells called G-protein-coupled receptors and mapping how they work.

The receptors stud the surface of cells, sensitising them to light, flavour, smells and body chemicals such as adrenaline and enabling cells to communicate with each other.

About a thousand of these kinds of receptor are known to exist throughout the body. They are essential not just for physiological processes but also for response to drugs.

"About half of all medications achieve their effect through G-protein-coupled receptors," the Nobel jury said.

Understanding the receptors provides the tools for "better drugs with fewer side effects," Nobel committee member Sven Lidin said.

G-protein-coupled receptors (GPCRs) are known to influence everything from sight, smell and taste to blood pressure, pain tolerance and metabolism.

They tell the inside of cells about conditions on the outside of their protective plasma membranes, to which the cells can form a response -- communicating with each other and with the surrounding environment.

This explains how cardiac cells know to raise the heart rate when we are startled, for example.

See original here:

US pair share chemistry Nobel for cell receptors

Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities

NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities

http://www.reportlinker.com/p01009930/Molecular-Imaging-Agents-Targets-Technology-Markets-and-Commercial-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Driven by advances in molecular probe design and biomarker detection methodologies, new imaging agents that can improve visualization of pathologies and cellular processes are changing the practice of diagnostic medicine. The ability of this new generation of contrast agents to detect metabolic changes at the molecular level has significant potential for improving visualization and quality of care. Targetable and activatable imaging agents are gaining interest for a wide range of diagnostic applications that include cardiology, neurology and soft tissue tumor detection. The number of healthcare conditions that can be effectively imaged noninvasively is expanding as a result of these innovative detection technologies. Targeted and activatable imaging agents offer a unique capability to generate unambiguous images by exploiting specific molecular targets, pathways or cellular processes. This new wave of imaging agents signals a paradigm shift in which the reagents take on new importance.

Highlights

Analyzes and assesses emerging imaging diagnostic candidates, their capabilities, benefits, limitations and potential

Profiles development-stage imaging agents and examines their clinical status and commercial prospects

Analyzes key industry alliances and partnerships by imaging modality, and examines the impact of next-generation imaging candidates on future imaging markets

Profiles market participants, their development activity and business strategies

Read more here:

Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities

Medical Imaging Markets: Molecular Imaging

NEW YORK, Oct. 11, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0234688/Medical-Imaging-Markets-Molecular-Imaging.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Molecular imaging techniques include nuclear medicine imaging positron emission tomography (PET) and single photon emission computed tomography (SPECT) and combination PET/CT and SPECT/CT techniques as well as ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) imaging that are used with molecular imaging agents.

Molecular imaging has evolved into a pillar of molecular medicine. It combines functional imaging with structural imaging so that specific in-vivo molecular processes can be identified and spatially pinpointed, often with the use of imaging contrast agents that bind to specific biological proteins. Molecular imaging is undertaking diagnostic and treatment roles as it enables physicians to pinpoint the locations of disease and track the progress of therapies. The same contrast agents used to highlight disease sites may even be able to carry drugs that can be selectively unleashed precisely where they are needed.

Medical Imaging Markets: Molecular Imaging offers complete market coverage of world markets for molecular imaging products for the following technologies:

For each of these modalities, the report provides current market size based on revenues to manufacturers of imaging systems used for molecular procedures, as well as forecasts of future revenues.

Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis, and serious market watchers in medical imaging industries, as well as those serving or investing in medical imaging companies, will want to keep abreast of this new market. As part of its comprehensive coverage,

includes:

Kalorama looks at the technologies currently used in molecular imaging but also examines novel research areas, such as:

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data provide multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives, clinicians and researchers.

Go here to read the rest:

Medical Imaging Markets: Molecular Imaging